Literature DB >> 24252047

A case of dermatomyositis with rhabdomyolysis, rescued by intravenous immunoglobulin.

Fumitaka Mizoguchi1, Kazuki Takada, Kinya Ishikawa, Hidehiro Mizusawa, Hitoshi Kohsaka, Nobuyuki Miyasaka.   

Abstract

We describe a case of severe dermatomyositis (DM) complicated by rhabdomyolysis, acute tubular necrosis, and hemophagocytosis. The case failed to respond to corticosteroids, but showed rapid and significant improvement after the addition of intravenous immunoglobulin (IVIG). While the prognosis of DM is poor when it is complicated by rhabdomyolysis, the early administration of IVIG has the potential to be the cornerstone of its management.

Entities:  

Keywords:  Dermatomyositis; Hemophagocytosis; IVIG; Rhabdomyolysis

Mesh：

Substances：

Year:  2013        PMID： 24252047     DOI： 10.3109/14397595.2013.843753

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN： 1439-7595            Impact factor:   3.023


  4 in total

Review 1.  Successful treatment of antisynthetase syndrome presenting as rhabdomyolysis with rituximab.

Authors:  Marwa Mohammed Sabha; Hermann Talom Simo; Rana Mohammed Shadid; Nezam Ibrahim Altorok
Journal:  Rheumatol Int       Date:  2018-04-11       Impact factor: 2.631

2.  Analysis and discussion of the rare complication of autoimmune encephalitis: Two case reports.

Authors:  Rong Li; Li Jiang; Xiu-Juan Li; Si-Qi Hong; Min Zhong; Yue Hu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

3.  Rhabdomyolysis-induced acute kidney injury in a patient with undifferentiated connective tissue disease: A case report and literature review rhabdomyolysis-induced AKI in a patient with UCTD.

Authors:  Hongxia Mai; Yuliang Zhao; Stephen Salerno; Yi Li; Letian Yang; Ping Fu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies.

Authors:  Yoji Komiya; Tetsuya Saito; Fumitaka Mizoguchi; Hitoshi Kohsaka
Journal:  Intern Med       Date:  2017-12-01       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.